期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

磺脲类药物与其他口服降糖药联合应用策略 被引量：3

Combination therapy of sulfonylureas and other oral antidiabetic drugs
暂未订购
导出
摘要 磺脲类（Sulfonylureas，SUs）药物是发现最早和使用最广泛的口服降糖药物。磺脲类药物作为单药治疗主要选择应用于新诊断的2型糖尿病患者（T2DM）非肥胖患者、用饮食和运动治疗血糖控制不理想时．年龄〉40岁、病程〈5年、空腹血糖〈10mmol/L时效果较好。随着疾病进展。
作者 包柄楠 周迎生
机构地区 首都医科大学附属北京安贞医院内分泌科
出处 《药品评价》 CAS 2011年第23期20-24,共5页 Drug Evaluation
关键词 磺脲类 联合用药 GLP-1 噻唑烷二酮类 二甲双胍 a-糖苷酶抑制剂
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献13

  • 1Genuth S.Management of the adult onset diabetic with sulfonylurea drug failure[J].Endocrinol Metab Clin Norht Am,1992,21(2):351-370.
  • 2Karyekar C,Donovan M,Allen E,et al.Efficacy and safety of saxagliptin combination therapy in US patients with type 2diabetes[J].Postgrad Med,2011,123(4):63-70.
  • 3Kikuchi M,Haneda M,Koya D,et al.Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2010,89(3):216-223.
  • 4Garber AJ,Foley JE,Banerji MA,et al.Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea[J].Diabetes Obes Metab,2008,10(11):1047-1056.
  • 5Wolffenbuttel BHR,Gomistr Squatrito S,et al.Addition of lowdose rosiglitazone to sulphonglarea therapy improves glycamic control in type 2 diabetic patients[J].Diaket Med,2000,17(1):40-47.
  • 6朱禧星,潘长玉,李光伟,史虹莉,田慧,杨文英,姜晶,孙晓春,C.DAVIES,王梅,周永浩.磺酰脲类药物合用马来酸罗格列酮治疗2型糖尿病的有效性和安全性观察——随机、双盲、对照、平行、多中心临床试验[J].中华内分泌代谢杂志,2003,19(3). 被引量：36
  • 7Chou HS,Palmer JP,Jones AR,et al.Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes[J].Diabetes Obes Metab,2008,10(8):626-637.
  • 8Irwin N,McKinney JM,Bailey CJ,et al.Effects of metformin on BRIN-BD11 beta cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas[J].Diabetes Obes Metab,2010,12(12):1066-1071.
  • 9Chen LL,Liao YF,Zeng TS,et al.Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients[J].Endocrine,2010,38(2):266-275.
  • 10Pareek A,Chandurkar N,Zawar S,et al.Evaluation of efficacy and tolerability of gliclazide and metformin combination:a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin[J].Am J Ther,2010,17(6):559 565.

二级参考文献21

  • 1征革凡,王金平,张辉,胡泽溪,刘娟,肖建中,陈仕明,曹辉碧,李光伟,胡英华,潘孝仁.拜糖平治疗非胰岛素依赖型糖尿病的临床观察[J].中华内分泌代谢杂志,1995,11(3):163-164. 被引量：43
  • 2陈家伦.新一代治疗糖尿病的药物──阿卡波糖[J].中华内分泌代谢杂志,1995,11(3):170-173. 被引量：53
  • 3Whiteomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs, 1995,4 : 1299-1309.
  • 4lmura H. A novel antidiabetic drug, troglitazone-reason for hope and concern. New Engl J Med, 1998,338:908-909.
  • 5Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2.diabetic patients. Diabetic Med, 2000,17:40-47.
  • 6Narayan KMV, Gregg EW, Fagot-Campagna A, et al. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract, 2000,50 ( Suppl 2 ) : S77-S84.
  • 7Turner RC, Cull CA, Frighi V, Glycemic control with diet, sulfonylurea, mefformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies ( UKPDS 49), JAMA1999,281:2005-2012.
  • 8Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulphonylureas. Diabetes, 2001,50 : A542.
  • 9Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Met Res Rev, 2002,18 : 127-134.
  • 10Barnett A. Rosiglitazone in type 2 diabetes: an evaluation in British lndo-Asian patients. Diabetic Med, 2001,18 :A40.

共引文献50

同被引文献42

  • 1刘海花.新的胰岛素增敏剂:吡格列酮应用进展[J].药物流行病学杂志,2004,13(5):240-242. 被引量：6
  • 2孟凡良.2型糖尿病应用吡格列酮和二甲双胍的作用比较[J].医药论坛杂志,2006,27(6):5-6. 被引量：2
  • 3吴永佩 吕红梅 颜青.加速临床药师制建设促进医疗团队的建立.中国医院,2009,13(11):2-5.
  • 4Chen YW, Chen YC, Wu CJ, et al. Massive Bilateral Pleural Effusion Associated with Use of Pioglitazone [J]. Clinical Therapeutics, 2008, 30(8):1485-1489.
  • 5Tan M, Johns D, Guillermo Gonzalez,et al. Effects of Pioglitazone and Glimepiride on Glycemic Control and Insulin Sensitivity in Mexican Patients with Type 2 Diabetes Mellitus:A Multicenter, Randomized,Double-Blind, Parallel-Group Trial[J].Clinical therapeutics,2004,26(5):680-93.
  • 6Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a Meta-analysis[J].Diabetes Res Clin Prac,2007,76( 2):279-289.
  • 7Kawamori R, Kadowaki T, Onji M,et al.Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan[J].Diabetes Research and Clinical Practice,2007,76:229-235.
  • 8Bhat R, Bhansali A,Bhadada S,et al. Effect of pioglitazone therapy in lean typel diabetes mellitus[J]. Diabetes Research and Clinical Practice,2007,78:349-354.
  • 9Dargie H J, Hildebrandt PR, Riegger GA,et al.A random ized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiog raohic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional and class I and II Heart Failure[J].J Am Coil Cardiol,2007,49:1696-1704.
  • 10米斯比.糖尿病药物的安全性该如何评价[J].糖尿病天地-临床刊,2009,3(1):34-37.

引证文献3

二级引证文献14

药品评价
2011年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部